Danny Dvir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Danny Dvir has a total of 619 co-authors. Here are the top co-authors by number of shared publications:
Ran Kornowski
Rabin Medical Center, Petah Tikva, Israel
12 shared publicationsJohn Webb
Division of Cardiology, St. Paul’s Hospital, Vancouver, Canada (J.W.).
10 shared publicationsMatheus Simonato
Yale School of Medicine, Yale University, New Haven, Connecticut, USA
10 shared publicationsMohamed Abdel-Wahab
Heart Center Leipzig at University of Leipzig , Leipzig , Germany
8 shared publications- Ron Waksman
Section of Interventional Cardiology MedStar Washington Hospital Center Washington DC USA
8 shared publications Didier Tchetche
Department of Cardiology, Clinique Pasteur, Toulouse, France
7 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Preprints.org
Clinical and Echocardiographic Predictors of Underutilization of Mitral Valve Intervention in Patients with Significant Mitral Regurgitation
Background: Mitral regurgitation (MR) is one of the most common valvular heart diseases and is associated with substantial morbidity and mortality if left untreated. Despite guideline recommendations, many patients with significant MR do not undergo surgical or transcatheter mitral valve intervention. We aimed to identify the clinical and echocardiographic characteristics associated with mitral valve intervention. Methods: We retrospectively analyzed 1,637 consecutive patients with moderate-to-severe or severe MR evaluated at Shaare Zedek Medical Center between December 2016 and December 2021. Patients were categorized into an intervention group (n = 191) and a conservatively managed group (n = 1,446). Clinical and echocardiographic characteristics were compared using univariable and multivariable logistic regression analyses. Results: Among 1,637 patients, only 191 (11.7%) underwent mitral valve intervention. Patients receiving intervention were younger (72.8 ± 12.9 vs. 76.5 ± 14.2 years; p = 0.001), more frequently male (57.6% vs. 48.0%; p = 0.013), and more commonly of Arab ethnicity (22.5% vs. 13.1%; p < 0.001). Severe MR (68.6% vs. 40.1%; p = 0.0004) and prosthetic mitral valve (6.8% vs. 2.3%; p = 0.0004) were more common among treated patients, whereas hypertension, advanced chronic kidney disease, and previous myocardial infarction were less common. Independent predictors of intervention were younger age (OR 0.98, 95% CI 0.97–0.99; p = 0.035), Arab ethnicity (OR 2.02, 95% CI 1.24–3.29; p = 0.005), and severe MR (OR 2.87, 95% CI 1.88–4.35; p < 0.001). Conclusions: Only a small proportion of patients with significant MR underwent mitral valve intervention. Older patients and those with ischemic or renal comorbidities were more likely to be managed conservatively. Earlier referral to dedicated Heart Valve Teams may improve access to guideline-directed treatment.
- 9 November 2026
- Published by MDPI AG in Preprints.org
Open AccessClinical and Echocardiographic Predictors of Underutilization of Mitral Valve Intervention in Patients with Significant Mitral Regurgitation
Background: Mitral regurgitation (MR) is one of the most common valvular heart diseases and is associated with substantial morbidity and mortality if left untreated. Despite guideline recommendations, many patients with significant MR do not undergo surgical or transcatheter mitral valve intervention. We aimed to identify the clinical and echocardiographic characteristics associated with mitral valve intervention. Methods: We retrospectively analyzed 1,637 consecutive patients with moderate-to-severe or severe MR evaluated at Shaare Zedek Medical Center between December 2016 and December 2021. Patients were categorized into an intervention group (n = 191) and a conservatively managed group (n = 1,446). Clinical and echocardiographic characteristics were compared using univariable and multivariable logistic regression analyses. Results: Among 1,637 patients, only 191 (11.7%) underwent mitral valve intervention. Patients receiving intervention were younger (72.8 ± 12.9 vs. 76.5 ± 14.2 years; p = 0.001), more frequently male (57.6% vs. 48.0%; p = 0.013), and more commonly of Arab ethnicity (22.5% vs. 13.1%; p < 0.001). Severe MR (68.6% vs. 40.1%; p = 0.0004) and prosthetic mitral valve (6.8% vs. 2.3%; p = 0.0004) were more common among treated patients, whereas hypertension, advanced chronic kidney disease, and previous myocardial infarction were less common. Independent predictors of intervention were younger age (OR 0.98, 95% CI 0.97–0.99; p = 0.035), Arab ethnicity (OR 2.02, 95% CI 1.24–3.29; p = 0.005), and severe MR (OR 2.87, 95% CI 1.88–4.35; p < 0.001). Conclusions: Only a small proportion of patients with significant MR underwent mitral valve intervention. Older patients and those with ischemic or renal comorbidities were more likely to be managed conservatively. Earlier referral to dedicated Heart Valve Teams may improve access to guideline-directed treatment.
- Open Access
- 24 June 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (34) , 109302
First-in-Human Mechanical Leaflet Modification of Native Aortic Stenosis During TAVR
- 24 June 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (34) , 109302
Open AccessFirst-in-Human Mechanical Leaflet Modification of Native Aortic Stenosis During TAVR
- Open Access
- 21 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2025-2039
First Large Comprehensive Core-Laboratory Evaluation of Implantation Depth and Clinical Outcomes in TAVR: Final Global Results from the Optimize PRO Prospective Study
- 21 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2025-2039
Open AccessFirst Large Comprehensive Core-Laboratory Evaluation of Implantation Depth and Clinical Outcomes in TAVR: Final Global Results from the Optimize PRO Prospective Study
- Open Access
- 5 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1678-1680
First-in-Human Transcatheter Aortic Root Tricuspidization of Stenotic Bicuspid Valves
- 5 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1678-1680
Open AccessFirst-in-Human Transcatheter Aortic Root Tricuspidization of Stenotic Bicuspid Valves
- Open Access
- 6 February 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 107055
First Report of Anchoring Via Trans-Leaflet Apposition Stent (ATLAS)
- 6 February 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 107055
Open AccessFirst Report of Anchoring Via Trans-Leaflet Apposition Stent (ATLAS)
- Open Access
- 24 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (3) , ytaf089
Simultaneous Cardioflow Optimisation to facilitate haemodynamic recovery after rapid ventricular pacing during transcatheter aortic valve implantation: a case series
Background: ‘Simultaneous CardioFlow optimization’ represents an innovative technique that effectively enhances post-pacing haemodynamic recovery during transcatheter aortic valve replacement. This technique was applied in two high-risk patients presenting with severe left main trunk stenosis with concomitant severe aortic stenosis (AS) and left ventricular dysfunction (LVD). Case summary: An 86-year-old and a 96-year-old patient were admitted with myocardial infarction. Angiography revealed severe left main trunk stenosis, while echocardiography demonstrated significant LVD and severe AS. Both cases were evaluated by the institutional multidisciplinary heart team. Considering the high surgical risk, a percutaneous management strategy was contemplated. Discussion: We postulated that performing left main trunk balloon angioplasty during rapid ventricular pacing would be better tolerated, compared with conventional balloon angioplasty, given the low coronary perfusion pressure at this stage. Additionally, coronary balloon angioplasty is expected to enhance coronary flow in the immediate post-pacing period, thus facilitating haemodynamic recovery. Both patients exhibited prompt improvement in hemodynamics following rapid ventricular pacing and had uncomplicated hospital stays. In patients with significant left main trunk stenosis accompanied by severe AS and concomitant left ventricular dysfunction, ‘simultaneous CardioFlow optimisation’ facilitates post-pacing haemodynamic recovery.
- 24 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (3) , ytaf089
Open AccessSimultaneous Cardioflow Optimisation to facilitate haemodynamic recovery after rapid ventricular pacing during transcatheter aortic valve implantation: a case series
Background: ‘Simultaneous CardioFlow optimization’ represents an innovative technique that effectively enhances post-pacing haemodynamic recovery during transcatheter aortic valve replacement. This technique was applied in two high-risk patients presenting with severe left main trunk stenosis with concomitant severe aortic stenosis (AS) and left ventricular dysfunction (LVD). Case summary: An 86-year-old and a 96-year-old patient were admitted with myocardial infarction. Angiography revealed severe left main trunk stenosis, while echocardiography demonstrated significant LVD and severe AS. Both cases were evaluated by the institutional multidisciplinary heart team. Considering the high surgical risk, a percutaneous management strategy was contemplated. Discussion: We postulated that performing left main trunk balloon angioplasty during rapid ventricular pacing would be better tolerated, compared with conventional balloon angioplasty, given the low coronary perfusion pressure at this stage. Additionally, coronary balloon angioplasty is expected to enhance coronary flow in the immediate post-pacing period, thus facilitating haemodynamic recovery. Both patients exhibited prompt improvement in hemodynamics following rapid ventricular pacing and had uncomplicated hospital stays. In patients with significant left main trunk stenosis accompanied by severe AS and concomitant left ventricular dysfunction, ‘simultaneous CardioFlow optimisation’ facilitates post-pacing haemodynamic recovery.
- 13 January 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (1) , 86-88
Native Leaflet Calcification
- 13 January 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (1) , 86-88
Native Leaflet Calcification
- Open Access
- 15 May 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (33) , 3031-3041
Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study
This trial sought to assess the safety and efficacy of ShortCut, the first dedicated leaflet modification device, prior to transcatheter aortic valve implantation (TAVI) in patients at risk for coronary artery obstruction. This pivotal prospective study enrolled patients with failed bioprosthetic aortic valves scheduled to undergo TAVI and were at risk for coronary artery obstruction. The primary safety endpoint was procedure-related mortality or stroke at discharge or 7 days, and the primary efficacy endpoint was per-patient leaflet splitting success. Independent angiographic, echocardiographic, and computed tomography core laboratories assessed all images. Safety events were adjudicated by a clinical events committee and data safety monitoring board. Sixty eligible patients were treated (77.0 ± 9.6 years, 70% female, 96.7% failed surgical bioprosthetic valves, 63.3% single splitting and 36.7% dual splitting) at 22 clinical sites. Successful leaflet splitting was achieved in all [100%; 95% confidence interval (CI) 94%–100.0%, P < .001] patients. Procedure time, including imaging confirmation of leaflet splitting, was 30.6 ± 17.9 min. Freedom from the primary safety endpoint was achieved in 59 [98.3%; 95% CI (91.1%–100%)] patients, with no mortality and one (1.7%) disabling stroke. At 30 days, freedom from coronary obstruction was 95% (95% CI 86.1%–99.0%). Within 90 days, freedom from mortality was 95% [95% CI (86.1%–99.0%)], without any cardiovascular deaths. Modification of failed bioprosthetic aortic valve leaflets using ShortCut was safe, achieved successful leaflet splitting in all patients, and was associated with favourable clinical outcomes in patients at risk for coronary obstruction undergoing TAVI. This pivotal prospective, multicentre study presents favourable clinical outcomes of ShortCut, the first dedicated leaflet modification device, prior to transcatheter aortic valve implantation (TAVI) in patients scheduled to undergo TAVI and at risk for coronary artery obstruction.
- 15 May 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (33) , 3031-3041
Open AccessLeaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study
This trial sought to assess the safety and efficacy of ShortCut, the first dedicated leaflet modification device, prior to transcatheter aortic valve implantation (TAVI) in patients at risk for coronary artery obstruction. This pivotal prospective study enrolled patients with failed bioprosthetic aortic valves scheduled to undergo TAVI and were at risk for coronary artery obstruction. The primary safety endpoint was procedure-related mortality or stroke at discharge or 7 days, and the primary efficacy endpoint was per-patient leaflet splitting success. Independent angiographic, echocardiographic, and computed tomography core laboratories assessed all images. Safety events were adjudicated by a clinical events committee and data safety monitoring board. Sixty eligible patients were treated (77.0 ± 9.6 years, 70% female, 96.7% failed surgical bioprosthetic valves, 63.3% single splitting and 36.7% dual splitting) at 22 clinical sites. Successful leaflet splitting was achieved in all [100%; 95% confidence interval (CI) 94%–100.0%, P < .001] patients. Procedure time, including imaging confirmation of leaflet splitting, was 30.6 ± 17.9 min. Freedom from the primary safety endpoint was achieved in 59 [98.3%; 95% CI (91.1%–100%)] patients, with no mortality and one (1.7%) disabling stroke. At 30 days, freedom from coronary obstruction was 95% (95% CI 86.1%–99.0%). Within 90 days, freedom from mortality was 95% [95% CI (86.1%–99.0%)], without any cardiovascular deaths. Modification of failed bioprosthetic aortic valve leaflets using ShortCut was safe, achieved successful leaflet splitting in all patients, and was associated with favourable clinical outcomes in patients at risk for coronary obstruction undergoing TAVI. This pivotal prospective, multicentre study presents favourable clinical outcomes of ShortCut, the first dedicated leaflet modification device, prior to transcatheter aortic valve implantation (TAVI) in patients scheduled to undergo TAVI and at risk for coronary artery obstruction.
- Open Access
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e243729
Culprit Lesion Coronary Intervention Before Complete Angiography in ST-Elevation Myocardial Infarction
Importance: Rapid reperfusion during primary percutaneous coronary intervention (PCI) is associated with improved outcomes among patients with ST-elevation myocardial infarction (STEMI). Although attempts at reducing the time from STEMI diagnosis to arrival at the catheterization laboratory have been widely investigated, intraprocedural strategies aimed at reducing the time to reperfusion are lacking.Objective: To evaluate the effect of culprit lesion PCI before complete diagnostic coronary angiography (CAG) vs complete CAG followed by culprit lesion PCI on reperfusion times among patients with STEMI.Design, Setting, and Participants: This open-label, prospective, randomized clinical trial was conducted between April 1, 2021, and August 31, 2022, among patients admitted to a tertiary center in Jerusalem, Israel, with a diagnosis of STEMI undergoing primary PCI. All patients were followed up for 1 year. Analysis was on an intention-to-treat basis.Intervention: Patients were randomized in a 1:1 ratio to undergo either culprit lesion PCI before complete CAG or complete CAG followed by culprit lesion PCI.Main Outcomes and Measures: A needle-to-balloon time of 10 minutes or less.Results: A total of 216 patients were randomized, with 184 patients (mean [SD] age, 62.9 [12.2] years; 155 men [84.2%]) included in the final intention-to-treat analysis; 90 patients (48.9%) were randomized to undergo culprit lesion PCI before CAG, and 94 (51.1%) were randomized to undergo to CAG followed by PCI. Patients who underwent culprit lesion PCI before complete CAG had a shorter mean (SD) needle-to-balloon time (11.4 [5.9] vs 17.3 [13.3] minutes; P < .001). The primary outcome of a needle-to-balloon time of 10 minutes or less was achieved for 51.1% of patients (46 of 90) who underwent culprit lesion PCI before CAG and for 19.1% of patients (18 of 94) who underwent complete CAG followed by culprit lesion PCI (odds ratio, 4.4 [95% CI, 2.2-9.1]; P < .001). Rates of adverse events were similar between groups. In a subgroup analysis, the effect of culprit lesion PCI before complete CAG on the primary outcome was consistent. There were no differences in rates of in-hospital, 30-day, and 1-year all-cause mortality.Conclusions and Relevance: In this randomized clinical trial of patients with STEMI, culprit lesion PCI before complete CAG resulted in shorter reperfusion times. Larger trials are needed to validate these results and to evaluate the effect on clinical outcomes.Trial Registration: ClinicalTrials.gov Identifier: NCT05415085
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e243729
Open AccessCulprit Lesion Coronary Intervention Before Complete Angiography in ST-Elevation Myocardial Infarction
Importance: Rapid reperfusion during primary percutaneous coronary intervention (PCI) is associated with improved outcomes among patients with ST-elevation myocardial infarction (STEMI). Although attempts at reducing the time from STEMI diagnosis to arrival at the catheterization laboratory have been widely investigated, intraprocedural strategies aimed at reducing the time to reperfusion are lacking.Objective: To evaluate the effect of culprit lesion PCI before complete diagnostic coronary angiography (CAG) vs complete CAG followed by culprit lesion PCI on reperfusion times among patients with STEMI.Design, Setting, and Participants: This open-label, prospective, randomized clinical trial was conducted between April 1, 2021, and August 31, 2022, among patients admitted to a tertiary center in Jerusalem, Israel, with a diagnosis of STEMI undergoing primary PCI. All patients were followed up for 1 year. Analysis was on an intention-to-treat basis.Intervention: Patients were randomized in a 1:1 ratio to undergo either culprit lesion PCI before complete CAG or complete CAG followed by culprit lesion PCI.Main Outcomes and Measures: A needle-to-balloon time of 10 minutes or less.Results: A total of 216 patients were randomized, with 184 patients (mean [SD] age, 62.9 [12.2] years; 155 men [84.2%]) included in the final intention-to-treat analysis; 90 patients (48.9%) were randomized to undergo culprit lesion PCI before CAG, and 94 (51.1%) were randomized to undergo to CAG followed by PCI. Patients who underwent culprit lesion PCI before complete CAG had a shorter mean (SD) needle-to-balloon time (11.4 [5.9] vs 17.3 [13.3] minutes; P < .001). The primary outcome of a needle-to-balloon time of 10 minutes or less was achieved for 51.1% of patients (46 of 90) who underwent culprit lesion PCI before CAG and for 19.1% of patients (18 of 94) who underwent complete CAG followed by culprit lesion PCI (odds ratio, 4.4 [95% CI, 2.2-9.1]; P < .001). Rates of adverse events were similar between groups. In a subgroup analysis, the effect of culprit lesion PCI before complete CAG on the primary outcome was consistent. There were no differences in rates of in-hospital, 30-day, and 1-year all-cause mortality.Conclusions and Relevance: In this randomized clinical trial of patients with STEMI, culprit lesion PCI before complete CAG resulted in shorter reperfusion times. Larger trials are needed to validate these results and to evaluate the effect on clinical outcomes.Trial Registration: ClinicalTrials.gov Identifier: NCT05415085
- 13 November 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (21) , 2615-2627
Clinical and Hemodynamic Outcomes of Balloon-Expandable Mitral Valve-in-Valve Positioning and Asymmetric Deployment
- 13 November 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (21) , 2615-2627
Clinical and Hemodynamic Outcomes of Balloon-Expandable Mitral Valve-in-Valve Positioning and Asymmetric Deployment